VEGFA and hepatocellular carcinoma: Antitumor immunotherapy has attracted increasing attention, and immune checkpoint inhibition with antivascular endothelial growth factor (VEGF) neutralizing antibodies has become first-line therapy for advanced-HCC patients [32].